Clinical trials: Allogeneic Hematopoietic Stem Cell Transplant Recipient
Transplantation, Hematopoietic Stem Cell
Monitoring of Measles-specific Immune Status in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients
Measles, a highly contagious disease, is potentially serious in adult allogenic hematopoietic stem cell transplant (allo-HSCT) recipients.
- Trial name
- MaRROwVacc (NCT05947864)
- Testing
- Biological samples (blood and oral fluid)
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Cytomegalovirus Infections, Haematological Malignancy
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient
This study consists of two parts: 1) Part 1, a retrospective part on 250 consecutive patients following allogeneic haematopoietic stem cell transplant (allo-HSCT) at the Royal Melbourne Hospital from 2012 to 2017, inclusive, and…
- Conditions
- Cytomegalovirus Infections, Haematological Malignancy, Organ or Tissue Transplant; Complications, Immune Suppression
- Trial name
- CReSCT (NCT03806764)
- Testing
- Blood sampling
- Where
- Australia
- Volunteers
- 370 people
- Sponsor
- Melbourne Health
Myelodysplastic/Myeloproliferative Neoplasm, Steroid Refractory GVHD
Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This is a single participant study of decidual stromal cells (DSC) for the treatment of steroid refractory graft-versus-host disease (GVHD) in a patient with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN).
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Steroid Refractory GVHD, Allogeneic Hematopoietic Cell Transplant
- Trial name
- DSC-SR (NCT04926194)
- Testing
- Decidual stromal cells (DSC)
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells
Trial Testing Safety of IL-21 NK Cells for Induction of R/R AML
This phase I trial studies the side effects of donor natural killer (NK) cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or has not responded to treatment (refractory).
- Conditions
- Allogeneic Stem Cell Transplant Recipient, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04220684
- Testing
- Cytarabine Hydrochloride, Fludarabine, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Sumithira Vasu
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia
Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant
This Phase II trial studies the side effects of denosumab and to see how well it works in treating patients with bone loss who have received a donor stem cell transplant.
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Osteopenia, Osteoporosis
- Trial name
- NCT03925532
- Testing
- Denosumab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Roswell Park Cancer Institute
Hypogammaglobulinemia
Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients
Tolerability of home subcutaneous immunoglobulin (ScIG) for replacement therapy for hypogammaglobulinemia in allogeneic HCT patients.
- Trial name
- ScIGalloHCT (NCT03401268)
- Testing
- subcutaneous immunoglobulin
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
CMV DNAemia Pre-engraftment
Pre-engraftment Cytomegalovirus DNAemia
Cytomegalovirus (CMV) DNAemia occurs frequently in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients.Both high-level and persistent virus DNAemia are known risk factors for CMV end-organ disease and perhaps…
- Trial name
- NCT03889028
- Where
- Spain
- Volunteers
- 878 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT01640301
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Cemiplimab in AlloSCT/SOT Recipients With CSCC
In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney…
- Trial name
- CONTRAC (NCT04339062)
- Testing
- Cemiplimab, Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Shingles
Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.
- Trial name
- NCT05554068
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Loyola University
Bronchiolitis Obliterans Syndrome (BOS), HSCT
Efficacy of an Anti-TSLP Monoclonal Antibody in the Management of Chronic Bronchial Disease Induced by Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Stem Cells Transplantation Recipients
Allogeneic hematopoietic stem cell transplantation (HSCT) is burdened with a high morbidity and mortality rates. Graft versus host disease (GVHD) is the clinical manifestation of an immune conflict.
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS), HSCT, Bronchial Disease
- Trial name
- IMMUNO-BOS (NCT07771855)
- Testing
- Tezepelumab
- Where
- 6 sites in France
- Volunteers
- 36 people
- Sponsor
- Hopital Foch
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant
This phase I trial studies the side effects and best dose of vorinostat when given together with fludarabine phosphate, clofarabine, and busulfan in treating patients with acute leukemia that is under control (remission) or has…
- Conditions
- Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Myelodysplastic Syndrome
- Trial name
- NCT02083250
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- M.D. Anderson Cancer Center
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation
TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
The purpose of this study is to evaluate the efficacy of tyrosine kinase inhibitor(TKI) therapy based on molecular monitoring of BCR/ABL levels in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)undergoing…
- Conditions
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia, Stem Cell Transplantation, Minimal Residual Disease
- Trial name
- NCT01883219
- Testing
- TKIs
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, CMV
VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol
The study is one of the researches carried out in the VIROMARKERS Project. The project VIROMARKERS is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101194735.
- Trial name
- NCT07286461
- Testing
- letermovir prophylaxis
- Where
- Germany
- Volunteers
- 290 people
- Sponsor
- University of Rome Tor Vergata
Acute Myeloid Leukemia, Hematopoietic Stem Cell Transplantation
Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML
The purpose of this study is to evaluate the efficacy of sorafenib for prophylaxis of leukemia relapse in allogeneic stem cell transplant (Allo-HSCT) recipients with FLT3-ITD positive acute myeloid leukemia (AML).
- Trial name
- NCT02474290
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Iron Overload
Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
This study has been designed to establish the efficacy and safety of deferasirox in patients with iron overload from 6 to 18 months after allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT01335035
- Testing
- deferasirox
- Where
- 9 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Transplantation Infection, Kidney Transplant; Complications
Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients
This is a pilot study designed to investigate the alterations in the gut microbiome that occur during the course of kidney transplantation, liver transplantation, allogeneic hematopoietic stem cells and mesenchymal stem cells…
- Conditions
- Transplantation Infection, Kidney Transplant; Complications, Stem Cell Transplant Complications, Liver Transplant; Complications
- Trial name
- NCT04281797
- Testing
- Intestinal microbiome new generation sequencing
- Where
- Belarus
- Volunteers
- 90 people
- Sponsor
- Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia
Allogeneic Stem Cell Transplant for CLL
This phase I/II trial studies the best dose and side effects of gemcitabine and how well it works with clofarabine and busulfan and donor stem cell transplant in treating participants with chronic lymphocytic leukemia.
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Richter Syndrome
- Trial name
- NCT01629511
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Vaccines, Pneumococcal Conjugate Vaccine
Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients
People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae.
- Trial name
- NCT00980655
- Testing
- 13vPnC, 23vPS
- Where
- 47 sites in United States, Belgium and 8 more
- Volunteers
- 251 people
- Sponsor
- Pfizer
Leukemia
Multiphasic Prehab Allo-HSCT
The purpose of this study is to implement a prehabilitation intervention to enhance recovery for people undergoing allogeneic stem cell transplant for hematologic malignancies.
- Trial name
- NCT05649371
- Testing
- Prehabilitation
- Volunteers
- 60 people
- Sponsor
- University of Calgary